Suppression of placental alkaline phosphatase biosynthesis by tunicamycin.
Placental alkaline phosphatase activity and immunoreactivity were inhibited in a parallel fashion in choriocarcinoma cells by tunicamycin, a protein glycosylation inhibitor. Tunicamycin suppressed placental alkaline phosphatase biosynthesis in addition to inhibiting protein glycosylation in general. An anti-placental alkaline phosphatase-precipitable polypeptide of 58,000 daltons was formed in the presence of this antibiotic. The 58,000-dalton polypeptide had a degradation rate similar to that of the glycosylated phosphatase monomer from control cultures. Tunicamycin suppressed placental alkaline phosphatase mRNA activity leading to the observed decrease in biosynthesis.
D000469:Alkaline Phosphatase / Q000096:biosynthesis* / Q000235:genetics; D002460:Cell Line; D002822:Choriocarcinoma / Q000201:enzymology*; D005260:Female; D005944:Glucosamine / Q000031:analogs & derivatives*; D006801:Humans; D007700:Kinetics; D010920:Placenta / Q000201:enzymology*; D011247:Pregnancy; D012333:RNA, Messenger / Q000235:genetics; D014415:Tunicamycin / Q000494:pharmacology*; D014594:Uterine Neoplasms / Q000201:enzymology*
D012333:RNA, Messenger; D014415:Tunicamycin; D000469:Alkaline Phosphatase; D005944:Glucosamine